Osteoporosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• RANKL 1
• PI3K 0
• NRF2 0
• AKT 0
• CTNNB1 0
• MAPK 0
• SIRT1 0
• mTOR 0
• AMPK 0
• PPAR 0
• STAT3 0
• ERK 0
• GPX4 0
• NLRP3 0
• YAP 0
• GLP-1 1
• TP53 0
• STING 0
• TNF 0
• HIF-1 0
• JAK 0
• METTL3 0
• IL-6 0
• PTEN 0
• VEGF 0
• CXCR4 0
• JNK 0
• MMP-9 0
• ESR1 0
• IL-4 0
• MEK 0
• PINK1 0
• SGLT2 0
• APP 0
• COX-2 0
• CSF1R 0
• DPP-4 0
• FTO 0
• HMGB1 0
• IL-1 0
• KIT 1
• APOE 0
• CD40 0
• CGRP 0
• EGFR 0
• EZH2 0
• FOXP3 0
• MYC 0
• TFEB 0
• ACE2 0
• AXL 0
• BRAF 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CCR5 0
• CDK4/6 0
• FGFR 0
• G6PD 0
• HSP90 0

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIA · F30

  Dissecting Age-related Changes in Stem Cell-based Bone-Gut Crosstalk

  University of California at Davis· Davis, United States· US$43,752 awarded in fiscal year 2026· until Sept 2029

• NIH OD · N02

  RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - AWARD MANAGEMENT - HIV @ Home

  Venturewell· Hadley, United States· US$4,599,325 awarded in fiscal year 2026· until Sept 2030

• NIH NIA · R41

  EC16 Nanoparticles: Bridging Oral Health and Alzheimer's Prevention via FAST Nanotechnology

  Camellix, Llc· Evans, United States· US$499,999 awarded in fiscal year 2026· until Sept 2027

• NIH NIDCR · R44

  Use of an Innovative Pre-Formed Structural Scaffold for Reconstruction of Segmental Bone Loss in a Zygomaticomaxillary Complex Model

  Revbio, Inc.· Lowell, United States· US$1,276,407 awarded in fiscal year 2026· until Aug 2028

• NIH NIA · R44

  Fibrinogen-coated albumin spheres to accelerate bone healing in older adults

  Fibroplate, Inc.· Las Vegas, United States· US$1,162,390 awarded in fiscal year 2026· until May 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Extending Female Reproductive Longevity: Neurovascular Control of the Ovarian Reserve (dOvary)

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €2,500,000· until Oct 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting Effective Plant Phosphopeptide–Calcium Formulations Using Machine Learning for Ca/Vitamin D3 and K2 Supplement Development via Pickering Emulsion (CaVita-Phos)

  Christian-Albrechts-Universitaet Zu Kiel· Kiel, Germany· EU contribution €202,125· until Sept 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Human Muscle-Bone Organoid-on-Chip to Study Bone Mechano- Adaptation via Optogenetic Control (BONE-TUNE)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €292,119· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Hypothalamic cell changes during menopause: the neuroendocrine origin of its metabolic alterations (HypoPause)

  Universidad de Santiago de Compostela· Santiago De Compostela, Spain· EU contribution €1,498,325· until Jan 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  EVOLUTIONARY MECHANISMS OF AGE-RELATED BONE LOSS ACROSS THE HUMAN AND HOMINID SKELETON (STAND UP)

  Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev· Munchen, Germany· EU contribution €401,232· until Dec 2028· 3 countries

10 of 690 running projects, newest first. Listed amounts together: US$351.6m + €61.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 17
• Organoids 1
• Mendelian Randomization Analysis 90
• CRISPR-Cas Systems 1
• Gene Expression Profiling 60
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 6
• Proteomics 23
• Metabolomics 25
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 10
• Xenograft Model Antitumor Assays 3
• Magnetic Resonance Imaging 73
• Machine Learning 79
• Deep Learning 38
• Cohort Studies 237
• Genome-Wide Association Study 83

• Identification of Chronic Stress-Related Biomarkers for Potential Diagnosis and Treatment of Osteoporosis: An Integrated Multi-omic and Clinical Data Analysis.

  Ther Innov Regul Sci, Jun 2026

• Exploring estrogen synthesis and metabolism related markers and immune dynamics in osteoporosis-insights from single-cell RNA sequencing and Mendelian randomization.

  Exp Gerontol, Feb 2026

• Single-cell RNA-sequencing-guided reactive oxygen species-scavenging hydrogel design for regeneration of osteoporotic bone.

  J Zhejiang Univ Sci B, Dec 2025

• Deciphering B Cell Heterogeneity and Pathogenic Mechanisms in Osteoporosis Through Single-Cell RNA Sequencing.

  Biomed Res Int, Dec 2025

• Biochemical activity of magnesium ions on human osteoblast migration.

  Biochem Biophys Res Commun, Aug 2020

See which targets of this disease your abstract mentions, and go to the people working on them.